99% Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome Get link Facebook X Pinterest Email Other Apps BusinessWire Get link Facebook X Pinterest Email Other Apps